Long-term follow-up of people with HIV who took part in earlier HIV-NAT studies
Follows adults with HIV treated with combination antiretroviral therapy over many years.
Plain-language title generated from the registry record
Registry title: A Long-term Follow-up of the HIV-NAT Cohort
Key facts
- Where
- Bangkok, ThailandSee the site
Where in Thailand
- HIV-NAT, Thai Red Cross AIDS Research CenterBangkok, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The HIV Netherlands Australia Thailand Research Collaboration
- Trial code
- NCT00411983
- Record updated
- 17 September 2026
- Original description
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.Read full original descriptionShow less
A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.
Inclusion: HIV infected patients( children and adults) previously participated HIV-NAT studies; HIV infected patients( children and adults) currently participate in HIV-NAT trials; Able to provide written consent.
Exclusion: Unable to provide written consent.